The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...

Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.

Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.

Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration ...

SSc and SLE are chronic autoimmune diseases with distinct and overlapping characteristics, including fibrosis in SSc and systemic inflammation in SLE. RNA sequencing identified differentially ...

Objective To investigate the relationship between adverse childhood experiences (ACEs) and health outcomes in childhood-onset ...

A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.